This trial studies financial difficulty in patients with chronic lymphocytic leukemia and multiple myeloma. Assessment of financial difficulty may help to better understand the financial impact of cancer and come up with ways to help patients avoid financial problems during treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03870633.
PRIMARY OBJECTIVES:
I. To estimate the proportion of patients with multiple myeloma (MM) and/or chronic lymphocytic leukemia (CLL) who report experiencing financial difficulty in the past 12 months.
SECONDARY OBJECTIVES:
I. To describe the association of patient report of financial difficulty with insurance status.
II. To describe the association of patient report of financial difficulty with receiving treatment at practices that report offering patients financial guidance through navigators or social workers, and controlling for patient socioeconomic status.
III. To describe the types of psychosocial, transportation and financial navigation interventions practices developing.
IV. To identify distinct patterns of financial burden among patients undergoing treatment for MM and/or CLL.
V. To examine the relationship between distinct patterns of financial burden with patient report of financial difficulty, patient socio-demographics, and patient disease characteristics.
VI. To estimate the proportion of patients with MM and/or CLL undergoing treatment who report receiving financial support in the past 12 months.
VII. To describe the association of patient report of receiving financial support with receiving treatment at practices offering patients financial guidance through navigators or social workers, and with socioeconomic status.
VIII. To describe the magnitude of patient concerns regarding treatment and costs of care.
IX. To describe the association of patient concerns regarding treatment and costs of care with patient socio-demographics, disease and practice characteristics.
X. To describe the association of financial difficulty with patient self-reported health and well-being.
OUTLINE:
Patients undergo medical chart abstraction within 1 week and complete telephone interview over 45-60 minutes within 8 weeks after registration.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationAlliance for Clinical Trials in Oncology
Principal InvestigatorRena M Conti